ADVERTISEMENT

Conference Report

AIDS 2022 — Bictegravir/emtricitabine/tenofovir alafenamide shows promise in HIV/HBV coinfection

Drishti Agarwal   |   04 August 2022

Takeaway

  • Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a safe and effective first-line treatment option for HIV/hepatitis B virus (HBV) coinfection.

Why this matters

  • Approximately 8% of patients with HIV have chronic HBV infection, with HIV/HBV coinfection rates mounting to 25% in areas endemic to both infections.
  • Most patients with HIV/HBV coinfection are...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right